BiomX (PHGE) EPS (Basic) (2018 - 2026)

BiomX (PHGE) posted EPS (Basic) of $7.38 for Q1 2026, down 34.25% sequentially from $11.23 in Q4 2025, and up 17.22% YoY from $6.3 in Q1 2025.

BiomX (PHGE) EPS (Basic) (2018 - 2026) Analysis & Trends

BiomX has reported EPS (Basic) for 9 years, with the latest figure at $7.38 in Q1 2026.

Quarterly EPS (Basic) rose 17.22% year-over-year to $7.38 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.26 (up 227.6% YoY) and the FY2025 annual result came in at $22.19, up 179.2% from the prior year.
EPS (Basic) slipped to $7.38 in Q1 2026 per PHGE's latest filing, from $11.23 in the prior quarter.
Over five years, EPS (Basic) peaked at $97.85 in Q4 2022 and troughed at -$173.41 in Q4 2023.
A 5-year average of -$13.45 and a median of $0.53 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2025: EPS (Basic) tumbled 277.21% in 2023, then jumped 240.95% in 2025.
Over 5 years, EPS (Basic) stood at $97.85 in 2022, then sank by 277.21% to -$173.41 in 2023, then jumped by 80.91% to -$33.1 in 2024, then jumped by 133.92% to $11.23 in 2025, then slumped by 34.25% to $7.38 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered $7.38, $11.23, and $5.55 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	12.62
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	7.59
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.23
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-0.72
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.18
10	BiomX	351,774.34	-816,225.66	-	7.38

Download Data